On September 9, 2019, BELLUS Health Inc. completed its initial public offering in the United States of 9,859,155 common shares at a price of US$7.10 per common share, for total gross proceeds of approximately US$70 million. BELLUS Health’s common shares are now dual-listed on the NASDAQ and the TSX under the trading symbol “BLU.” On September 17, 2019, an additional 1,320,296 common shares were issued at the same price for gross proceeds of US$9.37 million, following the exercise by the underwriters of their over-allotment option, resulting in aggregate gross proceeds of US$79.37 million.
BELLUS Health was represented by Davies Ward Phillips & Vineberg LLP, as Canadian counsel, with a team that comprised Sebastien Roy and Florence Bienvenu; and by Troutman Sanders LLP, as United States counsel, with a team that comprised Thomas M. Rose, Cot Eversole, Christine Kim and Shona Smith (Corporate), Mark Goldsmith and Joel Post (Tax), Heather Ettinger (Intellectual Property) and Robert Browne (Regulatory).
The underwriters were represented by Norton Rose Fulbright Canada LLP, as Canadian counsel, with a team that comprised Stephen Kelly, Amelie Metivier, Evelyn Li, Mark Bissegger, Julia Godolphin and Alexane Samson; and by Cooley LLP, as United States counsel, with a team that comprised John McKenna, Richard Segal, Div Gupta, Rose A. McKinley, Antoine Desroches and Darwin Ng.
